Сучасні підходи до досягнення оптимального метаболічного контролю в дітей із цукровим діабетом 1 типу
DOI:
https://doi.org/10.30978/DE2018-2-16Ключові слова:
діти, цукровий діабет 1 типу, аналоги інсуліну, безперервний моніторинг глікемії, інсулінова помпаАнотація
Одне з основних завдань лікування цукрового діабету в дітей – досягнення компенсації вуглеводного обміну з метою запобігання розвитку тривалих ускладнень і підвищення якості життя. Застосування аналогів інсуліну, інсулінових помп і систем безперервного моніторування глікемії значно розширили можливості контролю діабету. У статті розглянуто сучасні дані про цільові показники метаболічного контролю в дітей із цукровим діабетом 1 типу й засоби їх досягнення.
Посилання
American Diabetes Association. Children and Adolescents: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl.1):126-136.
Anderson BJ, Vangsness L, Connell A et al. Family conflict, adherence, and glycaemic control in youth with short duration type 1 diabetes. Diabet Med. 2002;19:635-642.
Battelino T, Phillip M, Bratina N et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34(4):795-800.
Beck RW, Buckingham B, Miller K, Wolpert H (Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group). Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009;32(11):1947-1953.
Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37(7):2034-2054.
Delamater AM, Wit M, McDarby V et al. ISPAD Clinical Practice Consensus Guidelines 2014. Psychological care of children and adolescents with type 1 diabetes. Pediatr Diabetes.2014;15(Suppl.20):232-244.
Edge J, Acerini C, Campbell F. An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch Dis Child. 2017;102(6):543-549.
Evans JM, Newton RW, Ruta DA et al. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ. 1999;319:83-86.
Galli-Tsinopoulou A, Stergidou D. Insulin analogues for type 1 diabetes in children and adolescents. Drugs Today (Barc). 2012;48(12):795-809.
Garg SK, Akturk HK. Flash Glucose Monitoring: The Future Is Here. Diabetes Technol Ther. 2017;19(Suppl.2):1-3.
Haller MJ, Stalvey MS, Silverstein JH. Predictors of control of diabetes: monitoring may be the key. J Pediatr. 2004;144:660-661.
Heinemann L. Variability of Insulin Action: Does It Matter? Insulin. 2008;3(1):37-45.
Helgeson VS, Palladino DK. Implications of psychosocial factors for diabetes outcomes among children with type 1 diabetes: a review.Soc Personal Psychol Compass. 2012;6:228-242.
Hermansen K, Fontaine P, Kukolja KK. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia. 2004;47(4):622-629.
Hietala K, Waden J, Forsblom C et al. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia. 2013;56:737-745.
Ji L, Guo X, Guo L. A multicenter evaluation of the performance and usability of a novel glucose monitoring system in Chinese adults with diabetes. J Diabetes Sci Technol. 2017;11:290-295.
Karges B, Rosenbauer J, Kapellen T. Hemoglobin A1c Levels and Risk of Severe Hypoglycemia in Children and Young Adults with Type 1 Diabetes from Germany and Austria: A Trend Analysis in a Cohort of 37,539 Patients between 1995 and 2012. PLoS Med. 2014;11(10):e1001742.
Karges B, Schwandt A, Heidtmann B, Kordonouri O. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA. 2017;318(14):1358-1366.
Katz ML, Kollman CR, Dougher CE. Influence of HbA1c and BMI on Lipid Trajectories in Youths and Young Adults WithType 1 Diabetes. Diabetes Care. 2017;40(1):30-37.
Kilpatrick ES, Rigby AS. A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes Data from the Diabetes Control and Complications Trial. Diabetes Care. 2008;31:2198-2202.
Kropff J, Bruttomesso D, Doll W, Farret A. Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes Metab. 2015;.17:343-349.
Lind M, Svensson AM, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2015;Feb.372(9):880-881.
Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111(5 Pt1):933-938.
Maahs DM. The Use of Insulin Pumps in Youth with Type 1 Diabetes. Diabetes Technology and Therapeutics. 2010;12(4):59-65.
Malik FS, Taplin CE. Insulin therapy in children and adolescents with type 1 diabetes. Paediatr Drugs. 2014;16(2):141-150.
Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB. A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes care. 2011;34:1011-1013.
McCarthy AM, Lindgren S, Mengeling MA et al. Factors associated with academic achievement in children with type 1 diabetes.Diabetes Care. 2003;26:112-117.
Nordwall M, Abrahamsson M, Dhir M, Fredrikson M. Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care. 2015;38(2):308-315.
O’Connell SM, Cooper MN, Bulsara MK, Davis EA. Reducing Rates of Severe Hypoglycemia in a Population-Based Cohort of Children and Adolescents With Type 1 Diabetes Over the Decade 2000—2009. Diabetes Care. 2011;34(11):2379-2380.
Perantie DC, Lim A, Wu J. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatric Diabetes. 2008;9(2):87-95.
Phillip M, Battelino T, Rodriguez H. Use of Insulin Pump Therapy in the Pediatric Age-Group. Diabetes Care. 2007;30(6):1653-1662.
Pihoker C, Forsander G, Fantahun B et al. ISPAD Clinical Practice Consensus Guidelines 2014. The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatr Diabetes. 2014;15 (Suppl.20):86-101.
Rewers MJ, Pillay K, de Beaufort C, Craig ME. ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2014;15 (Suppl.20):102-114.
Schwartz FL. Glycemic Variability in Type 1 Diabetes — Does It Matter? US Endocrinology. 2014;10:20-24.
Soupal J, Skrha J, Fajmon M. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technology and Therapeutics. 2014;16:198-203.
Tsalikian E, Fox L, Weinzimer S et al. (Diabetes Research in Children Network Study Group). Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatr Diabetes. 2012;13(4):301-307.
Virk SA, Donaghue KC, Cho YH et al. Association Between HbA1c Variability and Risk of Microvascular Complications in Adolescents With Type 1 Diabetes. J Clin Endocrinol Metab. 2016;101(9):3257-3263.
Ziegler R, Heidtmann B, Hilgard D. Wiss-Initiative: Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2011;12:11-17.
